|
1
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar
|
|
3
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in Cancer. Annu Rev Pathol. 9:287–314. 2014.
|
|
4
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang D, Qiu C, Zhang H, Wang J, Cui Q and
Yin Y: Human microRNA oncogenes and tumor suppressors show
significantly different biological patterns: from functions to
targets. PLoS One. 5:2010.
|
|
7
|
Hong L, Yang Z, Ma J and Fan D: Function
of miRNA in controlling drug resistance of human cancers. Curr Drug
Targets. 14:1118–1127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun YM, Lin KY and Chen YQ: Diverse
functions of miR-125 family in different cell contexts. J Hematol
Oncol. 6:62013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guan Y, Yao H, Zheng Z, Qiu G and Sun K:
MiR-125b targets BCL3 and suppresses ovarian cancer proliferation.
Int J Cancer. 128:2274–2283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang L, Luo J, Cai Q, et al:
MicroRNA-125b suppresses the development of bladder cancer by
targeting E2F3. Int J Cancer. 128:1758–1769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scott GK, Goga A, Bhaumik D, Berger CE,
Sullivan CS and Benz CC: Coordinate suppression of ERBB2 and ERBB3
by enforced expression of micro-RNA miR-125a or miR-125b. J Biol
Chem. 282:1479–1486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liang L, Wong CM, Ying Q, et al:
MicroRNA-125b suppressesed human liver cancer cell proliferation
and metastasis by directly targeting oncogene LIN28B2. Hepatology.
52:1731–1740. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kappelmann M, Kuphal S, Meister G,
Vardimon L and Bosserhoff AK: MicroRNA miR-125b controls melanoma
progression by direct regulation of c-Jun protein expression.
Oncogene. 32:2984–2991. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu LH, Li H, Li JP, et al: miR-125b
suppresses the proliferation and migration of osteosarcoma cells
through down-regulation of STAT3. Biochem Biophys Res Commun.
416:31–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bloomston M, Frankel WL, Petrocca F, et
al: MicroRNA expression patterns to differentiate pancreatic
adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA.
297:1901–1908. 2007. View Article : Google Scholar
|
|
16
|
Shi XB, Xue L, Yang J, et al: An
androgen-regulated miRNA suppresses Bak1 expression and induces
androgen-independent growth of prostate cancer cells. Proc Natl
Acad Sci USA. 104:19983–19988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vander Heiden M, Cantley LC and Thompson
CB: Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
|
|
18
|
Najafov A and Alessi DR: Uncoupling the
Warburg effect from cancer. Proc Natl Acad Sci USA.
107:19135–19136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou M, Zhao Y, Ding Y, et al: Warburg
effect in chemosensitivity: targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar
|
|
21
|
Nakano A, Tsuji D, Miki H, et al:
Glycolysis inhibition inactivates ABC transporters to restore drug
sensitivity in malignant cells. PLoS One. 6:e272222011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tong J, Xie G, He J, Li J, Pan F and Liang
H: Synergistic antitumor effect of dichloroacetate in combination
with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol.
2011:7405642011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Singh S, Singh PP, Roberts LR and Sanchez
W: Chemopreventive strategies in hepatocellular carcinoma. Nat Rev
Gastroenterol Hepatol. 11:45–54. 2014. View Article : Google Scholar
|
|
24
|
Abdel-Hamid NM and Morsy MA: Novel
biochemical pathways for 5-Fluorouracil in managing experimental
hepatocellular carcinoma in rats. J Membr Biol. 234:29–34. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshida H, Onda M, Tajiri T, et al:
Hepatocellular carcinoma responding to chemotherapy with 5-FU.
Hepatogastroenterology. 47:1120–1121. 2000.PubMed/NCBI
|
|
26
|
Lupini L, Bassi C, Ferracin M, et al:
miR-221 affects multiple cancer pathways by modulating the level of
hundreds messenger RNAs. Front Genet. 4:642013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Visone R, Russo L, Pallante P, et al:
MicroRNAs (miR)-221 and miR-222, both overexpressed in human
thyroid papillary carcinomas, regulate p27Kip1 protein levels and
cell cycle. Endocr Relat Cancer. 14:791–798. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ivanovska I, Ball AS, Diaz RL, et al:
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote
cell cycle progression. Mol Cell Biol. 28:2167–2174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou R, Li X, Hu G, Gong AY, Drescher KM
and Chen XM: miR-16 targets transcriptional corepressor SMRT and
modulates NF-kappaB-regulated transactivation of interleukin-8
gene. PLoS One. 7:e307722012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Henson BJ, Bhattacharjee S, O’Dee DM,
Feingold E and Gollin SM: Decreased expression of miR-125b and
miR-100 in oral cancer cells contributes to malignancy. Genes
Chromosomes Cancer. 48:569–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Balkhi MY, Iwenofu OH, Bakkar N, et al:
miR-29 acts as a decoy in sarcomas to protect the tumor suppressor
A20 mRNA from degradation by HuR. Sci Signal. 6:ra632013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Y, VandenBoom TG II, Wang Z, et al:
miR-146a suppresses invasion of pancreatic cancer cells. Cancer
Res. 70:1486–1495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Le MT, Teh C, Shyh-Chang N, et al:
MicroRNA-125b is a novel negative regulator of p53. Genes Dev.
23:862–876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rajabi H, Jin C, Ahmad R, McClary C, Joshi
MD and Kufe D: Mucin 1 Oncoprotein Expression Is Suppressed by the
miR-125b Oncomir. Genes Cancer. 1:62–68. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peschiaroli A, Giacobbe A, Formosa A, et
al: miR-143 regulates hexokinase 2 expression in cancer cells.
Oncogene. 32:797–802. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kefas B, Comeau L, Erdle N, Montgomery E,
Amos S and Purow B: Pyruvate kinase M2 is a target of the
tumor-suppressive microRNA-326 and regulates the survival of glioma
cells. Neuro Oncol. 12:1102–1112. 2010. View Article : Google Scholar : PubMed/NCBI
|
